Washington, January 3 (Xinhua) -- The U.S. Food and Drug Administration revised the emergency use authorization for the Pfizer new crown vaccine on the 3rd, approving one dose of Pfizer vaccine booster for 12- to 15-year-olds who have completed two doses of Pfizer vaccination.
People wait outside a COVID-19 vaccination van in New York, USA, on November 19, 2021. Xinhua News Agency (Photo by Guo Ke)
The U.S. Drug Administration said in a statement that the benefits of 12- to 15-year-olds receiving one dose of Pfizer vaccine booster after completing two doses of Pfizer vaccination can help prevent serious consequences such as infection with the new crown virus and its hospitalizations and deaths, and its benefits outweigh the potential risks.
The FDA said that after evaluating data from more than 6,300 people aged 12 to 15 in Israel who received Pfizer vaccine boosters, the agency believed that there were no new safety issues in this age group to receive booster needles, and no cases of myocarditis or pericarditis after vaccination with booster needles have been received so far.
In addition, the USC approved on the same day to shorten the interval between completing Pfizer vaccination and intensive injection vaccination for people aged 12 years and older from 6 months to 5 months.
The FDA also approved immunocompromised 5- to 11-year-olds to receive a third dose of Pfizer vaccine at least 28 days after receiving a second dose of Pfizer for stronger protection.
![Study says two doses of Pfizer vaccine reduced to 22.5 percent effectiveness against Omi kerong[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)